Nexstim Oy announced the presentation of the abstract “TMS as a part of multimodal management of safe glioma resection in the motor cortex” at the 60th Annual Meeting of the German Society of Neurosurgery.
Clinicians at the distinguished Department of Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt, Germany compared the results of non-invasive TMS, using Nexstim’s Navigated Brain Stimulation (NBS) System, and fMRI with the results of invasive direct cortical stimulation (DCS) in patients with tumors in or near the motor cortex. The clinicians noted that in all patients “TMS showed congruence with DCS. In contrast to fMRI, TMS and DCS enabled identification of eloquent cortex within the tumor.”
In addition, the Frankfurt clinicians concluded that “TMS (as part of Nexstim’s NBS System) may call into question categorizing tumors in the motor cortex as unresectable, since TMS anticipates information usually only enabled by invasive DCS.”
Jukka-Pekka Särkkä, Managing Director of Nexstim commented, The Frankfurt study confirms our belief that NBS overcomes the limitations of fMRI and we were pleased with the enormous interest in NBS at this important meeting.